SELECT misses on a secondary endpoint the coverage has not mentioned
A design note rather than a result: what the comparator was, and what that permits you to conclude.
Archive — March 2024
Page 4 of 5 of this archive, newest first.
Spain health authority warns on falsified tirzepatide pens
Reported from the analysis, not from a warning notice.
Halvard & Pike Apothecary of Portland, Maine enters a consent decree and stops sterile preparation
The observation that closes a facility is rarely the dramatic one.
Reading a certificate as a document rather than as a score
The purity figure is the least informative line on a well-constructed certificate and the only line most buyers read.
The imaging substudy is an afterthought in the protocol and the centrepiece of the debate
The composition data comes from imaging substudies enrolling a few score participants at selected sites. It is the best evidence available and it is thin.
Ireland caps liraglutide prescribing to 22 specialist centres
Efficacy was never the question in this appraisal. Duration of treatment was.
SURMOUNT-2 extension data: what happens after the trial stops
A design note rather than a result: what the comparator was, and what that permits you to conclude.
Turkey pharmacy body issues counselling standards for dulaglutide initiation
The evidence base is thin and the document says so, which is to its credit.
The slide that was not in the abstract
Reported from the sessions, and from the two hours afterwards.
From 0.25 to 2.4: reading a ladder as a series of ratios
What the published pharmacokinetics permit, what the labels state, and where the two diverge.
Why FGP can be entirely straightforward and still tell you nothing about bioburden
The Journal has read several hundred certificates from twenty companies. We set out what the documents actually cover, and what a reader is filling in from imagination.
India health authority warns on falsified exenatide pens
Reported from the analysis, not from a warning notice.
STEP 2 misses on a secondary endpoint the coverage has not mentioned
A design note rather than a result: what the comparator was, and what that permits you to conclude.
What the new Germany guidance says about stopping
The evidence base is thin and the document says so, which is to its credit.
Inspectors cite the consolidator trading as Meridian Freight Partners over sterility assurance
The observation that closes a facility is rarely the dramatic one.
Gallstones during rapid weight loss: drug, or weight loss?
We give background rates alongside trial rates, because an event occurring during treatment is not thereby caused by it.
Collapse temperature, and the hour of the cycle where shelf life is lost
The physics of the drying cycle explains why some cakes are matte and full-volume and others are glassy discs, and why the difference is not cosmetic.
The template economy: one certificate, many products
A blank certificate with the numbers left editable is an ordinary internal document. Its circulation as a finished record is the problem.
Why summer is a documented quality problem in this trade
The route did not close because of a rule about peptides.
A shortage listing ends. 10 pharmacies now have a business model and no legal basis for it.
The document is four pages. Three of them are about dates.
The quiet end of the relabeller trading as Vantris Bio
A proper account of an operation that existed, and of what closing it cost.
Why a result on one vial says less than the trade needs it to
What a laboratory can and cannot know about the provenance, storage history and representativeness of what lands on its bench.
A shortage listing ends. 6 pharmacies now have a business model and no legal basis for it.
The document is four pages. Three of them are about dates.
QSC declines, for the 21st time, to name its synthesis house
Documentation practice is the only part of vendor quality a buyer can assess before purchase.
Saudi Arabia declines to reimburse dulaglutide outside a specialist service
Efficacy was never the question in this appraisal. Duration of treatment was.
Inspectors cite the relabeller trading as Vantris Bio over sterility assurance
The observation that closes a facility is rarely the dramatic one.
A tested vial is evidence about a vial
The condition on arrival is recorded by some services and not others, and it is one of the more informative lines in a report.
The supply gap as a clinical event
Cost is the modal reason for discontinuation in every dataset we have seen, and it is absent from the clinical literature.
Why summer is a documented quality problem in this trade
The route did not close because of a rule about peptides.
What changed at CPC in March, and what the company will not say about it
Documentation practice is the only part of vendor quality a buyer can assess before purchase.
Sweden caps dulaglutide prescribing to 22 specialist centres
Efficacy was never the question in this appraisal. Duration of treatment was.
The quiet end of the online reseller trading as Adamant Research Supply
A proper account of an operation that existed, and of what closing it cost.
The interventions with trial support, and the much longer list without
Almost nothing in the standard management repertoire has been tested in a randomised trial in this specific population. We say what is extrapolated and from where.
Which results are findings and which are consequences of the weight loss
A substantial proportion of the abnormal results generated during rapid weight loss are consequences of the weight loss rather than findings about the person.
New Zealand pharmacy body issues counselling standards for tirzepatide initiation
The evidence base is thin and the document says so, which is to its credit.
The slide that was not in the abstract
Reported from the sessions, and from the two hours afterwards.
Inspectors cite the relabeller trading as Vantris Bio over sterility assurance
The observation that closes a facility is rarely the dramatic one.
The glucagon receptor arm, and why it is the hardest to reason about
Head-to-head data exists for some of these comparisons and not for others. This piece says which.
The named comparison we promised two years ago
Duplicate submissions under different names test within-laboratory repeatability, which is a different quantity from between-laboratory reproducibility.
What the new the United Arab Emirates guidance says about stopping
The evidence base is thin and the document says so, which is to its credit.